RESOURCES

Sequentify develops genomic samples processing products and technologies, prior to sequencing hardware loading

Comprehensive Resources on US Payer Policies for NGS

The following resources provide detailed insights into US payer policies regarding Next-Generation Sequencing. These include systematic reviews, policy analyses, case studies, and stakeholder surveys, offering a comprehensive view of the challenges, opportunities, and current trends in payer decision-making for genomic testing. Explore the table below for access to key publications and research findings in this field.

Type	Title	Year	Author	Pages
Systematic Literature Review	Payer Perspectives on Genomic Testing in the United States	2024	Julie Wiedower, Hadley Stevens Smith, Christopher L. Farrell, Veronica Parker, Laura Rebek, Stephanie Clark Davis	14
Payer Coverage Policy Review	Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing	2023	Conducted by ADVI, commissioned by the American Cancer Society Cancer Action Network	78
Policy and Market Analysis	Perspectives of US Private Payers on Insurance Coverage for Pediatric and Prenatal Exome Sequencing	2020	Julia R. Trosman, Christine B. Weldon, Anne Slavotinek, Mary E. Norton, Michael P. Douglas, Kathryn A. Phillips	9
Discrete Choice Experiment	Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment	2020	Devender S. Dhanda, David L. Veenstra, Dean A. Regier, Anirban Basu, Josh J. Carlson	9
Real-World Evidence Review	Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions	2020	Patricia A. Deverka, Michael P. Douglas, Kathryn A. Phillips	11
Stakeholder Survey Analysis	Stakeholders’ Views on the Value of Outcomes From Clinical Genetic and Genomic Interventions	2019	Maren T. Scheuner, Marcia M. Russell, Catherine Chanfreau-Coffinier, Jane Peredo, Elizabeth M. Yano, Alison B. Hamilton, Barbara Lerner, Dawn Provenzale, Sara J. Knight	10
Case Study	Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company From the Payer Perspective	2019	Mitchell Reitsma, John Fox, Pierre Vanden Borre, Matthew Cavanaugh, Yakov Chudnovsky, Rachel L. Erlich, Thomas E. Gribbin, Rachel Anhorn	11
Survey and Analysis	Preemptive Pharmacogenetic Testing: Exploring the Knowledge and Perspectives of US Payers	2019	Nicholas J. Keeling, Meagen M. Rosenthal, Donna West-Strum, Amit S. Patel, Cyrine E. Haidar, James M. Hoffman	9
Healthcare Policy Perspective	Delivering on the Value Proposition of Precision Medicine: The View From Healthcare Payers	2018	Jane Null Kogan, Philip Empey, Justin Kanter, Donna J. Keyser, William H. Shrank	3
Policy Analysis	Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative	2017	Julia R. Trosman, Christine B. Weldon, Michael P. Douglas, Allison W. Kurian, R. Kate Kelley, Patricia A. Deverka, Kathryn A. Phillips	10
Editorial	Payer View: How Do We Assess Quality in the Age of Precision Medicine	2016	Lee N. Newcomer	3
Policy Delphi Panel Study	Barriers to Clinical Adoption of Next-Generation Sequencing: Perspectives of a Policy Delphi Panel	2016	Donna A. Messner, Jennifer Al Naber, Pei Koay, Robert Cook-Deegan, Mary Majumder, Gail Javitt, Patricia Deverka, Rachel Dvoskin, Juli Bollinger, Margaret Curnutte	6
Cost-Effectiveness Perspective Analysis	Clinical Players and Healthcare Payers: Aligning Perspectives on the Cost–Effectiveness of Next-Generation Sequencing in Oncology	2015	Brett Doble, Paula Lorgelly	5